ARQT
NASDAQ HealthcareArcutis Biotherapeutics, Inc. - Common stock
Biotechnology
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
๐ Market Data
| Price | $23.35 |
|---|---|
| Volume | 1,003,387 |
| Market Cap | 2.92B |
| Beta | 1.770 |
| RSI (14-Day) | 44.6 |
| 200-Day MA | $22.84 |
| 50-Day MA | $23.86 |
| 52-Week High | $31.77 |
| 52-Week Low | $12.42 |
| Forward P/E | 19.37 |
| Price / Book | 15.20 |
๐ฏ Investment Strategy Scores
ARQT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (92/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (9/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ARQT in your text
Paste any article, transcript, or post โ the tool will extract ARQT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.